flutiform® pMDI offers:
Fine particle size
3.15 μm median particle size (MMAD)1*
*ICS component at 60 L/min inspiratory flow.
Improved asthma control across different real-world evidence studies1-3
More than 4,000 patients were enrolled in real-world evidence studies over 3 and 12 months5-7
- ffLUX Study5^
- ffAIRNESS Study6¶
- AffIRM Study7#
^ A significantly higher proportion of patients achieved controlled asthma after switching from fluticasone propionate/ salmeterol pMDI to flutiform® pMDI.5
¶ The percentage of patients with well-controlled asthma more than doubled, from 30.9% to 65.3%, after 12 months.6
# The percentage of patients with controlled asthma went from 29.4% to 67.4% at the end of a 12-month study.7
Warmer, less forceful plume vs fluticasone propionate/ salmeterol pMDI3
May reduce amount of drug that is deposited in the back of the throat and improve lung deposition‡
‡ Based on in vitro data which does not necessarily predict human clinical effect.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β₂ agonist; pMDI, pressurised metered-dose inhaler; MMAD, median mass aerodynamic diameter
flutiform® pMDI for adolescents & adults
flutiform® pMDI has demonstrated improved levels of asthma control compared to baseline (as per GINA guidelines4) over 3 and 12 months across different RWE studies enrolling more than 4,000 patients5-7
§ Based on Asthma Control Test score of ≥ 20.
Abbreviations: GINA, Global Initiative for Asthma; RWE, real-world evidence; pMDI, pressurised metered-dose inhaler
- ffLUX5: A randomised pragmatic trial changing from fluticasone propionate/ salmeterol pMDI to flutiform® pMDI (12 weeks) A significantly higher proportion of patients achieved controlled asthma after switching from fluticasone propionate/ salmeterol pMDI to flutiform® pMDI5
- ffAIRNESS6: Prospective, 1-year, non-interventional, multicentre study in Germany (12 months) The percentage of patients with controlled asthma increased from baseline of 30.9% to 65.3% after 12 months on flutiform® pMDI6
- AffIRM7: Real-world study to evaluate the safety and effectiveness of flutiform® pMDI in 2,539 patients with asthma (12 months) The percentage of patients with controlled asthma increased from baseline of 29.4% to 67.4% at the end of the study (12 months).7
Associated with a low rate of severe asthma exacerbations6-8
Long term therapy with flutiform® pMDI is associated with a low rate of severe asthma exacerbations both in RCTs (2.1%)8 and RWEs.6-7
Abbreviations: pMDI, pressurised metered-dose inhaler; RCT, randomised controlled trial; RWE, real-world evidence
flutiform® pMDI for children & adolescents
How can flutiform® pMDI help control asthma in children?
(aged 5 – 12 years)
flutiform® pMDI 50/5 µg is indicated for children 5 years and above2 and has demonstrated improvements in lung function and measures of asthma control in paediatric patients with asthma aged 5 – 12 years.9,10
- flutiform® pMDI 50/5 μg has demonstrated superiority to fluticasone propionate pMDI and non-inferiority to fluticasone propionate/ salmeterol pMDI for change in pre-dose FEV₁ to 2 hours post-dose over 12 weeks.9
- flutiform® pMDI 50/5 μg improves lung function and asthma control compared to baseline, with comparable efficacy to fluticasone propionate/ salmeterol pMDI and favourable safety and tolerability profile in children aged 5 to 12 years.10
- flutiform® pMDI 50/5 μg has not shown effects on plasma cortisol or children's growth.10
Abbreviations: pMDI, pressurised metered-dose inhaler; FEV₁, forced expiratory volume in 1 second
Join your colleagues and get access to exclusive content and news updates
- Newsletters with latest updates in asthma management selected by our panel of specialists
- Training and educational resources
- Latest updates on products and services offered
- Exclusive webinars from industry leading experts on the topics that matter to you
- Johal B, et al. Comb Prod Ther 2013;3(1–2):39-51.
- flutiform® SmPC. Last updated 13 April 2022. https://www.emcpi.com/pi/26954. Accessed 5 September 2022.
- Johal B, et al. Adv Ther 2015;32(6):567-579.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (Updated 3rd May 2022). Available at: https://ginasthma.org/wp-content/uploads/2022/05/GINA-Main-Report-2022-FINAL-22-05-03-WMS.pdf. Accessed 5 September 2022.
- Usmani OS, et al. J Allergy Clin Immunol Prac 2017;5:1378-87.
- Schmidt O, et al. Respir Med 2017;131:166-174.
- Backer V, et al. Ther Adv Respir Dis 2018;12:1-16.
- Papi A, et al. J Aerosol Med Pulm Drug Deliv. 2016;29:346-361.
- Płoszczuk A, et al. Ther Adv Respir Dis 2018;12:1-15.
- Emeryk A, et al. Ther Adv Respir Dis 2016;10:324-37.
®: FLUTIFORM is the Trademark of Jagotec AG used under licence by Mundipharma.
®: The ‘lung’ logo, is a Registered Trademark of Mundipharma.